Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the role of contraceptives in dermatology, particularly for acne treatment and managing patients on teratogens, but reports no new clinical results.

This review discusses the effectiveness and mechanisms of combined oral contraceptives in treating acne vulgaris but reports no new clinical results; the authors highlight their antiandrogenic effects for managing acne and related endocrine disorders.

This study found that LDE225, a novel Smo antagonist, shows potential as a topical treatment for basal cell carcinoma due to its high affinity binding and effective inhibition of tumor growth in preclinical models.

This randomized, controlled clinical trial found that combining 25 mg/d bicalutamide with 1 mg/d minoxidil for 24 weeks did not enhance hair density improvement in female pattern hair loss compared to 1 mg/d minoxidil alone, with no significant difference observed between the groups.

In this study, treatment with flutamide combined with a low-dose oral contraceptive significantly improved hirsutism in women with polycystic ovarian disease who did not respond to oral contraceptive treatment alone.

In this phase 3 trial, baricitinib showed effectiveness and safety in both adolescents and adults with severe alopecia areata, with adolescents achieving higher response rates despite more severe baseline conditions, suggesting the advantages of early treatment.

In this study, topical CUR61414 was effective in inhibiting basal cell carcinomas in mice, but no clinical activity was observed in human trials.

Baricitinib is a safe and effective treatment for severe alopecia areata.

This study found that ritlecitinib improved patient-reported outcomes related to hair growth in individuals with alopecia areata, with some experiencing clinically meaningful hair regrowth, although changes in emotional symptoms and activity limitations were minimal and similar across treatment groups.

This study suggests that lower-dose ethinyl estradiol formulations and progestin-only contraceptives may offer safer options for managing PCOS in obese women due to minimal metabolic effects.

This study found that men with early-onset androgenic alopecia are less responsive to the cardiometabolic effects of bromocriptine compared to men with normal hair growth.

This review discusses current treatments for cicatricial alopecia focused on reducing inflammation to prevent further hair loss and suggests auxiliary therapies to improve the appearance of remaining hair, without reporting new clinical results.

This study found that cyproterone acetate significantly reduced both serum 3α-AdiolG levels and hirsutism scores in women with idiopathic hirsutism, PCOS, or 21-hydroxylase deficiency, suggesting its effectiveness in treating excessive hair growth.

This study reported that ritlecitinib was generally well tolerated over 72 months in patients aged 12 and older with alopecia areata, with adverse events like headache and nasopharyngitis observed, and safety outcomes consistent with previous studies.

This study reported that newly synthesized progesterone derivatives significantly reduced prostate weight in testosterone-treated hamsters, with 5alpha-reductase inhibitory activity dependent on the size of the substituent at C-17.

In this study, patients with active lymphocytic cicatricial alopecia showed significant improvement using a three-stage treatment regimen involving Tofacitinib, Apremilast, and Crisaborole, with 93.5% experiencing marked improvement and only three mild adverse events reported.

In this study, ginsenoside 20(S)-protopanaxadiol-aglycone (PPD) was shown to downregulate androgen receptor expression and inhibit tumor growth in prostate cancer cells.

This review examined various treatments for hirsutism and found low to very low quality evidence suggesting that flutamide and spironolactone may help reduce hair growth, while metformin was ineffective.

This study found that spironolactone was not independently associated with increased breast cancer recurrence and may be considered for treating alopecia in survivors.

This study mapped potential targets and pathways for baicalin's action in androgenic alopecia, suggesting it may inhibit 5α-reductase and serve as an effective treatment ingredient.

This review discusses the use of different types of oral contraceptive pills and highlights their effectiveness, potential side effects, and contraindications without presenting new clinical data.

This study found that increased Bcl-2 protein expression after DPCP treatment was associated with hair regrowth in alopecia areata patients, suggesting its role in inhibiting apoptosis.

This paper addresses diagnostic criteria and treatment options for polycystic ovary syndrome, emphasizing lifestyle changes and combination oral contraceptives as primary management strategies, but it reports no new clinical results.

This analysis reports no significant differences between spironolactone and metformin for managing PCOS, noting spironolactone remains a potential off-label option for patients unable to use hormonal contraceptives, but larger studies are necessary to confirm its efficacy.

This study reported a rare case of pityriasis rubra pilaris-like skin reaction in an 18-year-old woman after starting ponatinib treatment for relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia, which resolved after treatment adjustment and did not recur over 15 months.

This article reviews the use of several medications for ovulation induction in polycystic ovary syndrome and hirsutism treatment, noting these uses are not FDA-approved; no new clinical results are provided.